Genomind, a Chalfont, PA-based personalized medicine company, closed a $5m financing.
The round was led by Claritas Capital.
The company intends to use the funds to grow operations and products.
Led by Dr. Ronald I. Dozoretz, Co-Founder and Chairman, Jay Lombard, DO, a neurologist and co-founder, and Scott A. Storrer, President and CEO, Genomind provides the Genecept™ Assay, a saliva-based genetic test that helps inform treatment decisions for patients with depression and other psychiatric disorders. It contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, autism, OCD and ADHD.
It is used by clinicians and patients in all 50 states.